The British drugmaker seeks to offset declining sales of COVID-19 medicines with its cancer, metabolic and rare disease drugs and Soriot said it is on track to deliverHe highlighted AstraZeneca's recent decision to build a manufacturing facility in Ireland instead of the UK as evidence of Britain becoming less attractive for drugmakers.
The VPAS began in 2019 to help make drugs more affordable for the national health system , by returning a proportion of funds based on the sales of branded prescription medicines when a maximum sales growth rate is exceeded.
Jim_Cornelius Where's the 'tidal wave' BorisJohnson ?
Brexit benefits
Time to roll out the official blaming of the remainer, metropolitan elite, left wing economic establishment, anti growth coalition, woke lefties who don't believe in the BREXIT fairy.